Here are the 10-K annual reports from Biogen Inc. (BIIB) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow BIIB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIIB filings page.
Biogen Inc. describes its 2025 business, strategy and major pipeline moves in neurology, specialized immunology and rare diseases. The company markets MS drugs such as VUMERITY and TYSABRI, SPINRAZA for SMA, SKYCLARYS for Friedreich ataxia, QALSODY for SOD1 ALS, LEQEMBI for early Alzheimer’s disease and ZURZUVAE for postpartum depression, alongside multiple biosimilars and anti‑CD20 revenue-sharing products with Genentech.
Key 2025 actions include acquiring Alcyone Therapeutics for about $85 million to control ThecaFlex DRx delivery technology, entering new collaborations with Dayra, Vanqua, City Therapeutics and Stoke with upfront payments ranging from $16 million to $165 million, and securing up to $250 million in litifilimab co-funding via a $200 million Royalty Pharma development financing recorded as an R&D offset. Biogen also issued $1.75 billion of 2025 senior notes, signed a 15.5‑year lease for a 580,000‑square‑foot Cambridge headquarters to support a planned 40% Massachusetts footprint reduction, advanced multiple Phase 3 programs (including felzartamab, salanersen and zorevunersen) and recorded numerous global label and access expansions for LEQEMBI, SPINRAZA, SKYCLARYS and QALSODY.